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ZIKA virus (ZIKA) has now become a global phenomenon. Since 2007, evidence of ZIKA
transmission has been reported over 72 countries and territories. The transmission of
ZIKA has made World Health Organization to categorize the situation under the ambit
of a health emergency. This situation is serious because there appears to be a highly
tangible link between infection during pregnancy and the occurrence of microcephaly
and Guillain–Barré syndrome. In the context of this emergency situation, this review
article intends to discuss the prevention and control strategies such as avoiding travel
to infected area, being careful from mosquito bites, take precautions to reduce the risk
of sexual transmission, and seek medical care for any acute illness with rash or fever.
This review is an attempt to analyze the results of those campaigns, keeping in view
the variables and constants that affect any such measures. Furthermore, this article will
suggest proactive measures that can be employed to effectively combat the epidemic
transmission of the ZIKA.
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INTRODUCTION
ZIKA is a member of family Flaviviridae and the genus Flavivirus. The virus is icosahedral,
enveloped, non-segmented, single-stranded, 10 kb positive-sense RNA genome that closely relates
to the Spondweni virus (Hayes, 2009; Faye et al., 2014; Hafiz et al., 2016). Apart from lipid
bilayer and one genome RNA, ZIKA contains three distinct types of structural proteins such
as envelope protein (E), M-membrane protein (M/prM) and capsid or core protein (C) and
seven non-structural proteins (Lindenbach and Rice, 2003; Dia et al., 2016). ZIKA infection is
caused by the bites of daytime-active Aedes mosquitoes such as Aedes aegypti and A. albopictus
(Malone et al., 2016). The virus was first isolated from Aedes africanus infected rhesus monkey
in 1947 and is named after the Ugandan ZIKA Forest (Dick, 1952; Weinbren and Williams,
1958). The parallel research indicated that A. aegypti has also the capability of transmitting
ZIKA to monkeys and mice (Boorman and Porterfield, 1956). This led to the suspicion that
the virus can possibly infect humans. The first major outbreak of ZIKA infection was reported
from the Island of Yap in 2007 followed by Brazil in 2015. The most commonly reported
symptoms of ZIKA are mild fever, skin rashes, joint pain, myalgia, and conjunctivitis (red
eyes). Many people infected with ZIKA do not get sick, people who get sick usually report a
number of symptoms, resembling the symptoms of dengue fever (Malone et al., 2016), with a
very low mortality rate. This is the primary reason that the prevention and control strategies
are rarely implemented in infected population; however, there is a need to prevent further
infections. The virus attracted the spotlight from public health officials because of its highly
suspected association with maternal–fetal transmission and the microcephaly in the infected
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fetus as well as other associated neurological abnormalities in
adults with Guillain–Barré syndrome (GBS). Several prevention
and control strategies have been discussed and implemented to
control the epidemic. The World Health Organization (WHO)
currently listed following 72 countries and territories where
evidence of ZIKA transmission has been reported since 2007
(WHO, 2016). In 2015 alone, the evidence of ZIKA transmission
was reported in 56 countries and territories; in 2016, it was
reported in five countries, whereas in 12 countries and territories
the evidence of ZIKA transmission could be in or before 2015.
Further, since February 2016, 12 countries have reported evidence
of person-to-person ZIKA transmission and over 12 countries
reported microcephaly and other CNS malfunctions associated
with ZIKA. In addition, four countries reported microcephalic
babies born from mothers in countries with no endemic ZIKA
transmission, but have traveled to ZIKA affected countries
in the past. Therefore, to minimize the transmission, and
associated effects including fetal microcephaly, the Centers for
Disease Control and Prevention (CDC) circulated an advisory,
particularly for the expecting women, to avoid or at least
postpone their visit to the areas where transmission rate is
high (Oliveira et al., 2016), since, the risk of infection could be
associated with travelers from Brazil to other countries. From
September 2014 to August 2015, nearly 2.8 million people travel
to and from Brazil to United Stated as shown in Figure 1
(Statista, 2016), suggesting that there is a high risk factor of ZIKA
infection.
Epidemiology
Because of the asymptomatic clinical course of ZIKA infection,
it is difficult to calculate precise global prevalence. It has not
been widely reported owing to its clinical resemblance with other
flavivirus infections, and difficulty in differential diagnosis.
The ZIKA has been reported in various hosts including
mosquitos, humans, and, monkeys through sporadic case reports,
seroprevalence surveys and entomological surveys in 14 different
countries across Africa, Asia, and Oceania (Ioos et al., 2014).
The virus may also pass from primary to secondary host through
blood transfusion via infected blood cells and sexual contact
(Figure 2). The ZIKA infection symptoms usually appear in 3–
12 days after the vector bite and end within 2–7 days after onset
of symptoms (Duffy et al., 2009).
In South America, Brazil reported first outbreak of ZIKA
around mid of 2015. Brazil Ministry of Health gave an estimated
figure of 440,000–1,300,000 suspected cases of patients infected
with ZIKA in December 2015 (ECDC, 2016). In the United States
as of May, 2016, a total of 472 cases of ZIKA were reported
that are travel-associated. In other US territories, a total of
three travel-associated cases and 658 locally acquired cases were
reported (CDC, 2016a). Microcephaly and congenital syndrome
associated with ZIKA are also prevalent in countries, which have
ZIKA outbreak as shown in Table 1.
CLINICAL PRESENTATION AND
DIAGNOSIS
As previously discussed ZIKA transmits to humans through
infected A. aegypti and A. albopictus mosquitoes. Further, if
infects pregnant mother, the virus can pass to the fetus and lead
to microcephaly. In Colombia, 12,000 pregnant women were
infected with ZIKA and there were no reported microcephaly
evidence in their babies as of May 2016 (Rasmussen et al., 2016).
However, in April 2016, the CDC declared ZIKA the cause of
microcephaly in Brazil (Rasmussen et al., 2016), yet outside
of Brazil a similar number of cases have not been reported.
In June 15, 2016, the WHO reported seven ZIKA associated
microcephaly cases in Colombia and 1500 confirmed cases in
Brazil (WHO, 2016). The results of a study in French Polynesia
provided the evidence that 1 in 100 pregnancies exposed in the
first and second trimester, resulted in microcephaly (Cauchemez
et al., 2016). However, for ZIKA, asymptomatic infection is
common, and only 20% of infected humans show symptoms like
FIGURE 1 | Number of travelers to and from Brazil to other countries (Statista, 2016).
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FIGURE 2 | ZIKA transmission cycle in humans.
TABLE 1 | ZIKA microcephaly and congenital syndrome by September
2016 (WHO, 2016).







acute fever, maculopapular rashes, conjunctivitis, and arthralgia.
Because of low mortality and mild symptoms, hospitalization
ratio is relatively lesser as compared to Ebola like infections
(Wojda et al., 2015).
The disease can be diagnosed by patient’s clinical signs and
symptoms, resembling to other mosquito-borne viral diseases.
The complete travel history of the patient to the infected areas can
lead the physicians to correct diagnosis. Although the mosquito
has been designated as the primary vector for ZIKA transmission,
other modes of transmission like blood transfusion and sexual
intercourse are also under consideration (Musso et al., 2015).
While the clinical differential diagnosis is not specific,
diagnosis can be authenticated by performing a reverse
transcriptase-polymerase chain reaction (RT-PCR) according to
the CDC-issued guidance. The ZIKA RNA is detectable in serum
after 7th days post-symptom onset. ZIKA RNA has been detected
in serum in non-pregnant patients and pregnant patients after
62 days post-symptom onset and 53 days of after last known
exposure in an asymptomatic pregnant women (Driggers et al.,
2016; Meaney-Delman et al., 2016). ZIKA has been detected
from number of body fluids, including urine, blood, saliva,
and amniotic fluid (Musso et al., 2014; Barzon et al., 2016;
Hills et al., 2016). However, one of the reports suggest that
urine samples are more useful for diagnosis of ZIKA infections
(Gourinat et al., 2015). The virus specific immunoglobulin M
(IgM) as well as neutralizing antibodies can also be detected
after 1 week of infection, but these detected antibodies are not
specific (Tappe et al., 2014). In addition, other rapid tests such
as reverse transcription loop-mediated isothermal amplification
(RT-LAMP) (Lee et al., 2011) and RNA-biosensors (Baeumner
et al., 2002) could be used as a first step for virus detection.
Therefore, there is a dire need to develop a bedside test for ZIKA,
to enable the clinicians for effective diagnosis of the patients
infected with the virus.
PUBLIC HEALTH RESPONSE TO
EPIDEMIC
Currently, there is no specific vaccine for the preventive
treatment of ZIKA infection. However, different groups of
scientists are working world over to develop the ZIKA vaccine,
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and hopefully will be available in couple of years (Daily Mail,
2016). For the effective disease control and prevention, the
surveillance system can be drawn by reviewing the models that
have already been used against dengue and chikungunya fever,
but it should not be limited to only these two viral diseases (Tami
et al., 2016).
The public health approaches that will be implemented for
prevention of ZIKA should be capable of acknowledging the
urbanization of diseases spreading through animal associated
with population explosion, international trade and easy modes
of intercontinental transportations. There are five clear strategies
delineated by the Weaver (2013) where the interventions by
public health authorities can be made. The first strategy is to
intercept the enzootic life cycle. In this strategy, it is advised
to stop the vector growth in its native environment; however,
this strategy would not be feasible for ZIKA as it is difficult
to control the vector. Another limitation to the strategy is that
there is no available vaccine for ZIKA that could be inoculated
in primates. The second strategy is to reduce the exposure of
vulnerable subjects to the vector, in case of humans, applying bed
nets and mosquito repellents that can decrease the exposure. The
third technique that can reduce the disease burden is to limit
the vector/source to the urban population. This could be done
through control via modulating the vectorial capacity of theAedes
mosquito. Limiting the travel to infected areas also minimizes
the risk of ZIKA. Fourth strategy could be the most helpful as
well as it is an active strategy where the vector reservoirs are
eliminated. In the case of ZIKA, proper drainage can reduce the
stagnant water reservoirs to inhibit uncontrolled reproduction of
mosquitoes. Adequate garbage management could also be used to
hinder the vector proliferation. The fifth intervention that can be
helpful is to avoid the recurrence of the disease where humans can
act as the source of the virus for infection in non-human primates
like monkeys. Avoiding mosquito bites to infected humans could
be the aiding strategy for the prevention of spill over (Weaver,
2013).
The intervention of public health authorities is important,
as the current epidemic is not confined to single geographic
location. Despite vector-based transmission, blood transfusion
could also be a cause of the spread among the patients having co-
morbidities. In the recent past, 3% of the blood donors in French
Polynesia were screened positive for ZIKA using PCR (Aubry
et al., 2015).
It has also been reported that the ZIKA was present in the
semen (Musso et al., 2015), therefore leading to a possibility
of transmission through the sexual intercourse. If it is a
sexually transmitted disease, the approaches used to avoid
sexual transmitted diseases can also be employed to avoid
the transmission. The contact tracing used in other sexual
transmitted disease can be used to identify the other infected
patients (LaMotte, 2016).
PREVENTION STRATEGIES
Till date, there is no curative medicine for the ZIKA disease,
so to contain the epidemic prophylactic measures are bifurcated
into following approaches: control vector density and personal
protection (Daily Mail, 2016).
Control Vector Density
The key measure to interrupt the transmission of viruses is to
control the vector density. One of such control measures is
Integrated Vector Management (IVM) recommended by WHO.
Using the IVM model, overall sustainability, efficacy and cost-
effectiveness of the strategy can be improved. The Integrated
Management Strategy for the Prevention and Control of Dengue
(IMS – Dengue) could be a basic model for ZIKA. Therefore,
participation and collaboration of different organizations would
play a great role in exploring IVM model. It has been reported
that the A. aegypti is found in wide range of larval habitats
both natural and manmade. There is a critical need of consistent
implementation of the three-pronged IVM Model (Gubler and
Clark, 1996). Some of the important control measures should
include the followings:
• Monitoring of household and common areas to eliminate
vector breeding sites, such as water reservoirs and waste
drainage pipes.
• Regular cleaning of garbage collection sites.
• Development of physical, biological, and/or chemical
methods to control mosquito breeding.
• Use of appropriate insecticides as per WHO
recommendations.
• Fumigation of cargoes at ports and borders to prevent
transport of larva by various means of transportation.
In addition to the above control measure, one of the key
control measures is to avoid contact with vector. Therefore,
personal prevention is very important to avoid sickness. Patients
suffering with ZIKA infection and their family members must be
well-educated about the risk of transmission. Use of mosquito
nets, wire-mesh doors and windows, skin protection, and use of
repellents are some of the key prevention measures that need to
be taken under consideration.
Environmental Management
There are different environmental intervention and
managements to control the growth of the Aedes species. In this
subclass, authorities should be enabled to implement reliable
water supply management, proper cleaning and maintenance
of water storage systems, adequate solid waste management
systems, and desirable alterations in human behaviors and
residence systems. This includes proper cleaning of streets,
maintenance and modifications of buildings/structures as well as
housing units such as use of mosquito screens/nets on windows
and mosquito proofing of water storages (Sikka et al., 2016).
Introduction of Bacteria into the Mosquito Population
A bacteria known as Wolbachia is present in approximately
60% of insects, commonly known as world’s most common
reproductive parasite in the world (EDP, 2016). Wolbachia
reduces the mosquito-to-human transmission events, ultimately
reducing the transmission of virus to the humans from mosquito;
the introduction of Wolbachia to offspring through the female
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mosquito’s egg will facilitate the beneficial epidemiological
effect of securing humans from the bites. When the males
with Wolbachia will mate with normal female mosquitos,
females fail to hatch eggs while on other hand, the infected
Wolbachia females will hatch eggs and produce offspring
that will carry the Wolbachia effect (Nguyen et al., 2015).
At the start, the technique will have a very limited effect
as there will be a very few Wolbachia infected mosquitos
present, but with the time, number of Wolbachia containing
mosquitos increase, the significant effect can be observed. This
approach has shown significant results to control dengue; it
may also contribute significantly to control the ZIKA epidemic
by limiting the ZIKA transmission since both ZIKA and
dengue share similar clinical manifestation (Lambrechts et al.,
2015).
Genetic Tailoring of the Mosquito
Another technique under consideration is to genetically modify
the mosquitoes and giving rise to the population of mosquitoes
whose offspring are not able to survive. Reducing the population
of mosquitoes, ultimately will reduce the mosquito’s bites to
humans as well as the vulnerable primates. Especially, using
A. aegypti OX513A that has previously used to control dengue
spread and hopefully it will help in controlling ZIKA spread
as well (Phuc et al., 2007). A. aegypti OX513A is a genetically
engineered strain, which is effective due to presence of release of
insects carrying a dominant lethal (RIDL) genetic system (Alphey
and Alphey, 2014). Similarly, offspring of OX513A, so the wild
females will also die; this will keep the threshold of population
needed for the disease spread. There are many benefits of
the genetically modified vectors, but the most important fact
is the dissemination of knowledge regarding capabilities of
genetically modified vector to the concerned governmental
officials, public health officials, and scientists (Alphey and
Alphey, 2014).
Scientists and organizations are working on the genetic
modification of the vectors and aware of the fact that transgenic
technologies are associated with several environmental and safety
concerns that still need to be addressed. There are several
ecological side effects like unintended spread to non-target
species; and horizontal transfer of the transgenes that should be
properly addressed to avoid any undesired outcome (Gabrieli
et al., 2014).
Personal Prevention Measure
In the area of known ZIKA infection outbreak, the patients
should avoid further contact with the vector to limit the
spread of virus to other healthy people in the community. The
community members should go through a proper awareness
and education regarding prevention. The community members
should be encouraged to act on the steps mentioned in Table 2.
Insect repellents like N, N-diethyl-3-methylbenzamide, 3-(N-
butyl-N-acetyl) amino propionic acid ethyl-ester or icaridin can
be used. There are no specific recommendations and restrictions
regarding use of these mosquito repellents, unless there is any
specific warning given on the label of the product (Gibbons,
2002).
In the first week of ZIKA infection, following preventive
measures should be followed:
• Aedes mosquito bites should be avoided.
• The patients are advised to stay under the bed-nets.
• Another community that is under great risk of getting
infected from the patients is the health workers. It is essential
to protect the health workers so that other hospitalized
patients might not get infected from the workers. In addition,
care should be taken during blood donations and organ
donations.
• Avoid sexual intercourse when traveling to infected area or
when one of the partner is infected with ZIKA.
• Pregnant women are advised not to visit the setting where
patients are resided. Similarly, pregnant women are advised
not to visit where the epidemic is present.
Vaccine Preparation
Multiple firms are looking to prepare ZIKA vaccine so this
virus can be cured and does not ail our next generations. In
Japan, Takeda Pharmaceutical, Co. Ltd has created a team to
TABLE 2 | Prevention recommendation (copied from Sikka et al., 2016).
Strategy Action
Control vector design • Diligent management and control of environmental factors.
• Eliminate or reduce vector breeding sites in common areas.
• Conduct mass sanitation campaigns to educate the public.
• Ensure Mosquitoes are removed within the predetermined radius of critical places like schools, hospitals,
transport terminals, using risk stratification paradigms.
• In areas with viral activity, use mosquito adulticidal sprays to interrupt ZIKA transmission.
• Ensure proper monitoring and follow-up during integrated actions for vector control.
Preventative measure Individual protection
• Encourage Individuals to use Bed-nets.
• Appropriate clothing to cover exposed skin.
• Use repellents.
Household/residential protection
• Encourage Installation and use of wire-mesh screens on doors and windows.
• Once per week emptying, cleaning, turning over, and disposal of containers that can hold water inside or
outside the houses to reduce any mosquito breeding sites.
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investigate the propensity for creating a vaccine (Reuters, 2016).
In India, Bharat Biotech is looking in creating vaccine for
the virus. It is reported that two possible vaccines are under
process in India. In USA, Johnson and Johnson, Pfizer Inc.
and Merck & Co. Inc. are evaluating the tendency of previous
vaccines to combat ZIKA. Sanofi SA from France also launched
a program to create ZIKA vaccine. All in all, pharmaceutical
firms around the world are trying to create a vaccine for this
virus, suggesting that a ZIKA vaccine is at ground zero. Till then
preventive measures is the best way to avoid this virus (Reuters,
2016).
A group of researchers performed a drug repurposing
screen of around 6000 compounds and identified some novel
compounds that either suppress or inhibit ZIKA infection-
induced caspase-3 activity in different neural cells. In addition,
10 different inhibitors of cyclin-dependent kinases inhibited
ZIKA replication (Xu et al., 2016). One of these compounds
are already existing drug, Niclosaminde and another potentially
active against ZIKA is PHA-690509 (Xu et al., 2016). The results
are still preminary and after successfull animal trails might be
available to humans.
In another study, ZIKA-117, an antibody derived from the
blood of ZIKA infected people potentially protect developing
fetuses from the ravages of the ZIKA virus in mice. The antibody
treatment inhibit the virus in the mother and protect the fetus
(Sapparapu et al., 2016). However, development of ZIKA vaccine
would be promising for long-lasting immunity against the virus
than short-term antibody treatment.
BRIEF HISTORY AND TRAVELERS
RECOMMENDATIONS
In 1947, Alexander Haddon and George Dick first identified
ZIKA in monkey while studying yellow fever in the ZIKA forest
of Uganda. Subsequently, the same virus was isolated from the
Aedes species of mosquitoes in the same forest of Uganda. In
1950, antibodies against ZIKA were detected in humans, and in
FIGURE 3 | Journey of ZIKA from Uganda to the Americas.
TABLE 3 | Recommendations to travelers (copied from Sikka et al., 2016).
Traveler status Recommendations
Prior to departure • Travelers are advised to protect themselves from mosquito bites during stay.
• Use Mosquito repellents, wear appropriate clothing to minimize skin exposure.
• Use insecticides and bed-nets.
• Educate travelers about signs and symptoms of ZIKA/dengue/chikungunya virus in order to
identification and to reduce the time to required medical attention.
During visit • Avoidance of mosquito-infested areas.
• Avoidance of mosquito bites.
• Proactive and proper use of bed-nets and/or insecticide.
• Seek professional care in case there are symptoms of ZIKA/dengue/Chikungunya
Upon return • Travelers should contact appropriate health care provider in case ZIKA infection is suspected. Due
to some symptomatic overlap, this is also applies to dengue and chikungunya viruses.
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1968, ZIKA was isolated from humans in Nigeria. With time, the
ZIKA spread to other parts of Africa as well as Asia. However,
until 2007, no cases of ZIKA infection was found outside Africa
and Asia, except an outbreak in Yap Island and French Polynesia
in 2013. In 2015, the first case of ZIKA infection was detected in
Brazil and has speak to more than 50 countries in the Americas
(Figure 3).
Since there is a great risk of ZIKA infection due to travelers
traveling from ZIKA infected regions to other non-infected
regions, necessary precautions need to be taken. At present, there
is no recommendation from the WHO as to travel bans to the
affected countries. However, it is the government responsibility
to educate the public while traveling to the areas known for
epidemic spread (Table 3). Travelers should be advised to carry
necessary measures if traveling to ZIKA stricken regions. In
addition, appreciate information about the symptoms of ZIKA
infection and prevention should be handy at airports, bus
terminals, railways stations, and so on. This information could be
also printed on travel documents such as air tickets or webpages.
It is very important that upon returning from ZIKA prone
areas, travelers should contact their healthcare providers before
returning home.
CONCLUSION
ZIKA with no doubt took the world as a storm because of
Aedes mosquitoes in South America. The virus entered and
propagated in the country with conditions favorable for ZIKA
like high population density, lack of immunity in targets and
viral mutations. Global warming is a contributor in widespread
of ZIKA as well (Ai et al., 2016). On the face of earth, no country
is safe form ZIKA until preparation of vaccine. Countries having
Aedes mosquito is on high alert, every day a new case emerges
from other part of the world. ZIKA is progressing very fast and
next few months are very crucial for stopping the attacks of
Aedes mosquitos. High population directly affect the cases of
ZIKA. So, if the virus outbreaks in those countries like India,
China and USA, it would be impossible to control this virus. The
current most workable suggestion to pregnant mothers is to avoid
traveling to ZIKA affected areas. This is the best chance we have
got till now, more research is necessary on this subject to find the
cure for the disease. Cases of ZIKA has to be analyzed in detail to
check the relationship of ZIKA and genetic mutation of Aedes to
help understand why ZIKA is carried out in this type of mosquito
(CDC, 2016b).
When ZIKA was identified, it caught us by surprise and no
time could be leveraged to do anything in stopping this virus
but there are major implications for researchers and doctors in
studying ZIKA. It is still unidentified that how many more viruses
of this type are present in our atmosphere (Lambrechts et al.,
2015). Due to globalization, ZIKA can land anywhere through
any channel. Global climate change and urban crowding also
give way for ZIKA to grow. Maybe it is time when we need
to rethink our public health infrastructure and disease-control
strategies.
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